Skip header and navigation

Refine By

38499 records – page 1 of 3850.

1,3-Butadiene and leukemia among synthetic rubber industry workers: exposure-response relationships.

https://arctichealth.org/en/permalink/ahliterature166384
Source
Chem Biol Interact. 2007 Mar 20;166(1-3):15-24
Publication Type
Article
Date
Mar-20-2007
Author
Hong Cheng
Nalini Sathiakumar
John Graff
Robert Matthews
Elizabeth Delzell
Author Affiliation
University of Alabama at Birmingham, Ryals School of Public Health, Department of Epidemiology, Birmingham, AL, USA. hcheng@ms.soph.uab.edu
Source
Chem Biol Interact. 2007 Mar 20;166(1-3):15-24
Date
Mar-20-2007
Language
English
Publication Type
Article
Keywords
Butadienes - adverse effects
Canada - epidemiology
Carcinogens - chemical synthesis - chemistry - toxicity
Chemical Industry - manpower - statistics & numerical data
Confidence Intervals
Dimethyldithiocarbamate - adverse effects
Humans
Leukemia, Lymphoid - chemically induced - epidemiology
Leukemia, Myeloid - chemically induced - epidemiology
Likelihood Functions
Male
Middle Aged
Occupational Exposure - statistics & numerical data
Proportional Hazards Models
Rubber - adverse effects - chemical synthesis - chemistry
United States - epidemiology
Abstract
Previous research updated the mortality experience of North American synthetic rubber industry workers during the period 1944-1998, determined if leukemia and other cancers were associated with several employment factors and carried out Poisson regression analysis to examine exposure-response associations between estimated exposure to 1,3-butadiene (BD) or other chemicals and cancer. The present study used Cox regression procedures to examine further the exposure-response relationship between several unlagged and lagged, continuous, time-dependent BD exposure indices (BD parts per million (ppm)-years, the total number of exposures to BD concentrations >100 ppm ("peaks") and average intensity of BD) and leukemia, lymphoid neoplasms and myeloid neoplasms. All three BD exposure indices were associated positively with leukemia. Using continuous, untransformed BD ppm-years the regression coefficient (beta) from an analysis that controlled only for age was 2.9 x 10(-4) (p
PubMed ID
17123495 View in PubMed
Less detail

1,3-Butadiene: exposure estimation, hazard characterization, and exposure-response analysis.

https://arctichealth.org/en/permalink/ahliterature186649
Source
J Toxicol Environ Health B Crit Rev. 2003 Jan-Feb;6(1):55-83
Publication Type
Article
Author
K. Hughes
M E Meek
M. Walker
R. Beauchamp
Author Affiliation
Existing Substances Division, Environmental Health Directorate, Health Canada, Environmental Health Centre, Tunney's Pasture PL0802B1, Ottawa, Ontario, Canada K1A 0L2.
Source
J Toxicol Environ Health B Crit Rev. 2003 Jan-Feb;6(1):55-83
Language
English
Publication Type
Article
Keywords
Animals
Butadienes - metabolism - toxicity
Canada - epidemiology
Carcinogens, Environmental - toxicity
Environmental Exposure
Hazardous Substances - toxicity
Humans
Mutagens - toxicity
Neoplasms - chemically induced - epidemiology
Occupational Diseases - chemically induced - epidemiology
Risk assessment
Abstract
1,3-Butadiene has been assessed as a Priority Substance under the Canadian Environmental Protection Act. The general population in Canada is exposed to 1,3-butadiene primarily through ambient air. Inhaled 1,3-butadiene is carcinogenic in both mice and rats, inducing tumors at multiple sites at all concentrations tested in all identified studies. In addition, 1,3-butadiene is genotoxic in both somatic and germ cells of rodents. It also induces adverse effects in the reproductive organs of female mice at relatively low concentrations. The greater sensitivity in mice than in rats to induction of these effects by 1,3-butadiene is likely related to species differences in metabolism to active epoxide metabolites. Exposure to 1,3-butadiene in the occupational environment has been associated with the induction of leukemia; there is also some limited evidence that 1,3-butadiene is genotoxic in exposed workers. Therefore, in view of the weight of evidence of available epidemiological and toxicological data, 1,3-butadiene is considered highly likely to be carcinogenic, and likely to be genotoxic, in humans. Estimates of the potency of butadiene to induce cancer have been derived on the basis of both epidemiological investigation and bioassays in mice and rats. Potencies to induce ovarian effects have been estimated on the basis of studies in mice. Uncertainties have been delineated, and, while there are clear species differences in metabolism, estimates of potency to induce effects are considered justifiably conservative in view of the likely variability in metabolism across the population related to genetic polymorphism for enzymes for the critical metabolic pathway.
PubMed ID
12587254 View in PubMed
Less detail

1,005 delayed days: a study of adult psychiatric discharge.

https://arctichealth.org/en/permalink/ahliterature244608
Source
Hosp Community Psychiatry. 1981 Apr;32(4):266-8
Publication Type
Article
Date
Apr-1981
Author
P A Barrette
Source
Hosp Community Psychiatry. 1981 Apr;32(4):266-8
Date
Apr-1981
Language
English
Publication Type
Article
Keywords
Adult
Canada
Hospitals, Community
Hospitals, Psychiatric - organization & administration
Humans
Length of Stay
Patient Acceptance of Health Care
Patient Discharge
Abstract
Delay in discharge of psychiatric patients frequently is attributed to the lack of available community resources, or to the unwillingness of the patient or his family to accept discharge or transfer to another facility. The role of the psychiatric system itself rarely is mentioned as a factor. A study of 138 psychiatric patients in a Canadian community hospital in 1978 showed that 35 per cent were judged to be delayed in their discharge. By far the greatest source of delay was the administration of the various psychiatric services within the system. Delayed patients were found to be statistically similar to nondelayed patients, except for the delayed patients tendency to be poorer and to be overrepresented on two of the six wards studied. The cost implications of the delays in discharge are discussed, as are suggestions for solving the problems within the administrative framework.
PubMed ID
7227988 View in PubMed
Less detail

The 1 alpha-hydroxylase locus is not linked to calcium stone formation or calciuric phenotypes in French-Canadian families.

https://arctichealth.org/en/permalink/ahliterature206213
Source
J Am Soc Nephrol. 1998 Mar;9(3):425-32
Publication Type
Article
Date
Mar-1998
Author
P. Scott
D. Ouimet
Y. Proulx
M L Trouvé
G. Guay
B. Gagnon
L. Valiquette
A. Bonnardeaux
Author Affiliation
Service de Néphrologie, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.
Source
J Am Soc Nephrol. 1998 Mar;9(3):425-32
Date
Mar-1998
Language
English
Publication Type
Article
Keywords
25-Hydroxyvitamin D3 1-alpha-Hydroxylase - genetics - metabolism
Adult
Calcium - urine
Canada
European Continental Ancestry Group - genetics
Family Health
Female
France - ethnology
Genetic Linkage
Genetic Markers - genetics
Humans
Kidney Calculi - enzymology - genetics
Male
Middle Aged
Nuclear Family
Pedigree
Phenotype
Vitamin D - blood
Abstract
Calcium urolithiasis is often associated with increased intestinal absorption and urine excretion of calcium, and has been suggested to result from increased vitamin D production. The role of the enzyme 1 alpha-hydroxylase, the rate-limiting step in active vitamin D production, was evaluated in 36 families, including 28 sibships with at least a pair of affected sibs, using qualitative and quantitative trait linkage analyses. Sibs with a verified calcium urolithiasis passage (n = 117) had higher 24-h calciuria (P = 0.03), oxaluria (P = 0.02), fasting and postcalcium loading urine calcium/creatinine (Ca/cr) ratios (P = 0.008 and P = 0.002, respectively), and serum 1,25(OH)2 vitamin D levels (P = 0.02) compared with nonstone-forming sibs (n = 120). Markers from a 9-centiMorgan interval encompassing the VDD1 locus on chromosome 12q13-14 (putative 1 alpha-hydroxylase) were analyzed in 28 sibships (146 sib pairs) of single and recurrent stone formers and in 14 sibships (65 sib pairs) with recurrent-only (> or = 3 episodes) stone-forming sibs. Two-point and multipoint analyses did not reveal excess in alleles shared among affected sibs at the VDD1 locus. Linkage of stone formation to the VDD1 locus could be excluded, respectively, with a lambda d of 2.0 (single and recurrent stone formers) and 3.25 (recurrent stone formers). Quantitative trait analyses revealed no evidence for linkage to 24-h calciuria and oxaluria, serum 1,25(OH)2 vitamin D levels, and Ca/cr ratios. This study shows absence of linkage of the putative 1 alpha-hydroxylase locus to calcium stone formation or to quantitative traits associated with idiopathic hypercalciuria. In addition, there is coaggregation of calciuric and oxaluric phenotypes with stone formation.
PubMed ID
9513904 View in PubMed
Less detail

1 Canadian Field Hospital in Haiti: surgical experience in earthquake relief.

https://arctichealth.org/en/permalink/ahliterature122035
Source
Can J Surg. 2012 Aug;55(4):271-4
Publication Type
Article
Date
Aug-2012
Author
Max Talbot
Bethann Meunier
Vincent Trottier
Michael Christian
Tracey Hillier
Chris Berger
Vivian McAlister
Scott Taylor
Author Affiliation
1 Canadian Field Hospital, Canadian Forces, Montreal, QC. max_talbot@hotmail.com
Source
Can J Surg. 2012 Aug;55(4):271-4
Date
Aug-2012
Language
English
Publication Type
Article
Keywords
Canada
Disaster Planning - organization & administration
Earthquakes
Female
Haiti
Hospitals, Packaged - organization & administration
Humans
International Cooperation
Male
Multiple Trauma - etiology - surgery
Operating Rooms
Relief Work - organization & administration
Surgical Procedures, Operative - statistics & numerical data
Abstract
The Canadian Forces' (CF) deployable hospital, 1 Canadian Field Hospital, was deployed to Haiti after an earthquake that caused massive devastation. Two surgical teams performed 167 operations over a 39-day period starting 17 days after the index event. Most operations were unrelated to the earthquake. Replacing or supplementing the destroyed local surgical capacity for a brief period after a disaster can be a valuable contribution to relief efforts. For future humanitarian operations/disaster response missions, the CF will study the feasibility of accelerating the deployment of surgical capabilities.
Notes
Cites: Disasters. 2000 Sep;24(3):262-7011026159
Cites: Prehosp Disaster Med. 2003 Oct-Dec;18(4):278-9015310039
Cites: Disaster Manag Response. 2005 Jan-Mar;3(1):11-615627125
Cites: Mil Med. 2007 May;172(5):471-717521092
Cites: Prehosp Disaster Med. 2008 Mar-Apr;23(2):144-51; discussion 152-318557294
Cites: Ann Intern Med. 2010 Jun 1;152(11):733-720197507
Cites: Prehosp Disaster Med. 2009 Jan-Feb;24(1):9-1019557952
Cites: Science. 2010 Feb 5;327(5966):638-920133550
Cites: Nature. 2010 Feb 18;463(7283):878-920164905
Cites: N Engl J Med. 2010 Mar 18;362(11):e3820200362
Cites: Prehosp Disaster Med. 2009 Jan-Feb;24(1):3-819557951
PubMed ID
22854149 View in PubMed
Less detail

The 1st Annual Awards for Action on HIV/AIDS and Human Rights.

https://arctichealth.org/en/permalink/ahliterature182022
Source
Can HIV AIDS Policy Law Rev. 2002 Dec;7(2-3):1, 20-3
Publication Type
Article
Date
Dec-2002
Author
Thomas Kerr
Thomas Haig
Source
Can HIV AIDS Policy Law Rev. 2002 Dec;7(2-3):1, 20-3
Date
Dec-2002
Language
English
French
Publication Type
Article
Keywords
Awards and Prizes
Canada
HIV Infections
Human Rights
Humans
Physicians
Abstract
The 1st Annual Awards for Action on HIV/AIDS and Human Rights were awarded to the Vancouver Area Network of Drug Users and to Dr. Wan Yanhai, a Chinese physician and activist. The international attention and media coverage of the awards was heightened by the fact that the Chinese government had detained Dr. Wan for disclosing information about unsanitary blood collection practices in Henan province. An international outcry led to Dr. Wan's release on 20 September 2002.
PubMed ID
14719485 View in PubMed
Less detail

1st Canadian conference on hepatitis C.

https://arctichealth.org/en/permalink/ahliterature191313
Source
Can Nurse. 2001 Aug;97(7):14-6
Publication Type
Conference/Meeting Material
Date
Aug-2001

The 1st step: a personal health-care planner from the Canadian Cancer Society.

https://arctichealth.org/en/permalink/ahliterature229611
Source
J Palliat Care. 1990;6(2):48-50
Publication Type
Article
Date
1990
Author
C. Jamieson
Source
J Palliat Care. 1990;6(2):48-50
Date
1990
Language
English
Publication Type
Article
Keywords
Canada
Humans
Neoplasms - psychology
Patient Education as Topic - methods
Voluntary Health Agencies
PubMed ID
2376807 View in PubMed
Less detail

A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.

https://arctichealth.org/en/permalink/ahliterature206818
Source
Chest. 1998 Jan;113(1):131-41
Publication Type
Article
Date
Jan-1998
Author
R. Grossman
J. Mukherjee
D. Vaughan
C. Eastwood
R. Cook
J. LaForge
N. Lampron
Author Affiliation
Department of Respiratory Medicine, Mount Sinai Hospital, Toronto, ON.
Source
Chest. 1998 Jan;113(1):131-41
Date
Jan-1998
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Anti-Infective Agents - adverse effects - economics - therapeutic use
Bronchitis - drug therapy - economics
Canada
Chronic Disease
Ciprofloxacin - adverse effects - economics - therapeutic use
Cost-Benefit Analysis
Female
Follow-Up Studies
Health Care Costs
Hospitalization - economics
Humans
Male
Middle Aged
Predictive value of tests
Quality-Adjusted Life Years
Recurrence
Treatment Outcome
Abstract
To evaluate the costs, consequences, effectiveness, and safety of ciprofloxacin vs standard antibiotic care in patients with an initial acute exacerbation of chronic bronchitis (AECB) as well as recurrent AECBs over a 1-year period.
Randomized, multicenter, parallel-group, open-label study.
Outpatient general practice.
A total of 240 patients, 18 years or older with chronic bronchitis, with a history of frequent exacerbations (three or more in the past year) presenting with a type 1 or 2 AECB (two or more of increased dyspnea, increased sputum volume, or sputum purulence).
The assessment included AECB symptoms, antibiotics prescribed, concomitant medications, adverse events, hospitalizations, emergency department visits, outpatient resources such as diagnostic tests, procedures, and patient and caregiver out-of-pocket expenses. Patients completed the Nottingham Health Profile, St. George's Respiratory Questionnaire, and the Health Utilities Index. The parameters were recorded with each AECB and at regular quarterly intervals for 1 year. These variables were compared between the ciprofloxacin-treated group and the usual-care-treated group.
Patients receiving ciprofloxacin experienced a median of two AECBs per patient compared to a median of three AECBs per patient receiving usual care. The mean annualized total number of AECB-symptom days was 42.9+/-2.8 in the ciprofloxacin arm compared to 45.6+/-3.0 days in the usual-care arm (p=0.50). The overall duration of the average AECB was 15.2+/-0.6 days for the ciprofloxacin arm compared to 16.3+/-0.6 days for the usual-care arm. Treatment with ciprofloxacin tended to accelerate the resolution of all AECBs compared to usual care (relative risk=1.20; 95% confidence interval [CI], 0.91 to 1.58; p=0.19). Treatment assignment did not affect the interexacerbation period but a history of severe bronchitis, prolonged chronic bronchitis, and an increased number of AECBs in the past year were associated with shorter exacerbations-free periods. There was a slight, but not statistically significant, improvement in all quality of life measures with ciprofloxacin over usual care. The only factors predictive of hospitalization were duration of chronic bronchitis (odds ratio=4.6; 95% CI, 1.6, 13.0) and severity of chronic bronchitis (odds ratio=4.3; 95% CI, 0.8, 24.6). The incremental cost difference of $578 Canadian in favor of usual care was not significant (95% CI, -$778, $1,932). The cost for the ciprofloxacin arm over the usual care arm was $18,588 Canadian per quality-adjusted life year gained. When the simple base case analysis was expanded to examine the effect of risk stratification, the presence of moderate or severe bronchitis and at least four AECBs in the previous year changed the economic and clinical analysis to one favorable to ciprofloxacin with the ciprofloxacin-treated group having a better clinical outcome at lower cost ("win-win" scenario).
Treatment with ciprofloxacin tended to accelerate the resolution of all AECBs compared to usual care; however, the difference was not statistically significant. Further, usual care was found to be more reflective of best available care rather than usual first-line agents such as amoxicillin, tetracycline, or trimethoprim-sulfamethoxazole as originally expected. Despite the similar antimicrobial activities and broad-spectrum coverage of both ciprofloxacin and usual care, the trends in clinical outcomes and all quality of life measurements favor ciprofloxacin. In patients suffering from an AECB with a history of moderate to severe chronic bronchitis and at least four AECBs in the previous year, ciprofloxacin treatment offered substantial clinical and economic benefits. In these patients, ciprofloxacin may be the preferred first antimicrobial choice.
PubMed ID
9440580 View in PubMed
Less detail

38499 records – page 1 of 3850.